In vitro ovicidal activity of current and under-development scabicides - which treatments kill scabies eggs?

Scabies is highly prevalent worldwide with a significant DALYs global burden, affecting 100-200 million people annually.¹ In hyper-endemic tropical regions, the link with secondary bacterial infections is increasingly recognised. Group A streptococcal and staphylococcal pyoderma can cause bacteraemia,² glomerulonephritis and acute rheumatic fever potentially leading to rheumatic heart disease. Current scabies treatments are few in number and suboptimal. As neuroinhibitors they are expected to kill motile stages but could be poorly ovicidal. Emerging drug resistances in the parasites are a further concern.